Cepheid Plans Assay Expansion Beyond HAI Market, Additional Sales Hires Later This Year | GenomeWeb
This story originally appeared in Biocommerce Week, a newsletter that has been discontinued.
 
Cepheid officials said last week that the firm has devised a five-year plan for assay development that will take it beyond its current focus on hospital-acquired infections and into other infectious diseases and oncology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.